Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD9OVI)

Drug Name

MEDI1191 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukine 12 (IL-12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ABP 654	DM0GXWT	Plaque psoriasis	EA90.0	Phase 3	[3]
Ad-RTS-hIL-12	DMCNTFW	Glioblastoma of brain	2A00.00	Phase 2	[4]
GEN-1	DMJN09S	Ovarian cancer	2C73	Phase 2	[5]
Tavokinogene telseplasmid	DMZX0VF	Melanoma	2C30	Phase 2	[6]
M9241	DMZUM67	Pancreatic cancer	2C10	Phase 1	[7]
YH010	DMA1T66	Aggressive cancer	2A00-2F9Z	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03946800) A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
3	Clinical pipeline report, company report or official report of Amgen
4	Clinical pipeline report, company report or official report of Ziopharm Oncology.
5	Clinical pipeline report, company report or official report of Celsion.
6	Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
7	Clinical pipeline report, company report or official report of EMD Serono.
8	Clinical pipeline report, company report or official report of Biocytogen